Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -581.07% is 95% above its 4-year average of -10654.33%, near the high end of its 4-year range (-111587.92%–-79.30%).
82.66% above its 12-month average of -3350.87%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2139.43%.
EBITDA MARGIN
-581.07%
EBITDA MARGIN AVG TTM
-3350.87%
EBITDA MARGIN AVG 3Y
-9203.97%
EBITDA MARGIN AVG 5Y
-10654.33%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+82.66%
CURRENT VS 3Y AVG
+93.69%
CURRENT VS 5Y AVG
+94.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ovid Therapeutics Inc.
Market Cap
$448.87M
EBITDA Margin
-581.07%
TTM Avg
-3350.87%
3Y Avg
-9203.97%
5Y Avg
-10654.33%
Market Cap
$448.06M
EBITDA Margin
-1349.20%
TTM Avg
-1349.20%
3Y Avg
-1349.20%
5Y Avg
-1349.20%
Market Cap
$445.26M
EBITDA Margin
-14.39%
TTM Avg
-19.65%
3Y Avg
-40.36%
5Y Avg
-40.72%
Market Cap
$442.26M
EBITDA Margin
-184.73%
TTM Avg
-138.06%
3Y Avg
-2467.18%
5Y Avg
-2497.88%
Market Cap
$437.38M
EBITDA Margin
-16.58%
TTM Avg
-87.69%
3Y Avg
-357.20%
5Y Avg
-653.36%
Market Cap
$430.46M
EBITDA Margin
-232.13%
TTM Avg
-495.69%
3Y Avg
-578.57%
5Y Avg
-532.48%
Market Cap
$429.11M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | $448.87M | -581.07% | -3350.87% | -9203.97% | -10654.33% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.06M | -1349.20% | -1349.20% | -1349.20% | -1349.20% |
| NeuroPace, Inc. (NPCE)vs › | $445.26M | -14.39% | -19.65% | -40.36% | -40.72% |
| NRC Health (NRC)vs › | $454.82M | 21.99% | 25.40% | 28.98% | 31.97% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $442.26M | -184.73% | -138.06% | -2467.18% | -2497.88% |
| Assembly Biosciences, Inc. (ASMB)vs › | $437.38M | -16.58% | -87.69% | -357.20% | -653.36% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $437.65M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $430.46M | -232.13% | -495.69% | -578.57% | -532.48% |
| NeoGenomics, Inc. (NEO)vs › | $429.11M | 0.24% | -1.36% | -6.49% | -5.53% |
| Sight Sciences, Inc. (SGHT)vs › | $470.76M | -47.32% | -54.85% | -73.89% | -85.45% |
Gross Margin
100.0%
EBITDA Margin
-581.1%
Operating Margin
-585.2%
Net Margin
-2178.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2139.43% |
| 2025-12-31 | -1709.75% |
| 2025-09-30 | -9475.00% |
| 2025-06-30 | -79.30% |
| 2025-03-31 | -9545.38% |
| 2024-12-31 | -13897.37% |
| 2024-09-30 | -7547.40% |
| 2024-06-30 | -12052.66% |
| 2024-03-31 | -11676.35% |
| 2023-12-31 | -12709.86% |
| 2023-09-30 | -10901.83% |
| 2023-06-30 | -18713.33% |
| 2023-03-31 | -22343.94% |
| 2022-12-31 | -25903.05% |
| 2022-09-30 | -111587.92% |
| 2022-03-31 | -1120.36% |
| 2021-03-31 | 84.76% |
| 2020-12-31 | -377.13% |
| 2020-09-30 | -236.11% |
